Klothea BIO, Inc

Klothea Bio is a preclinical biotechnology company developing next-generation longevity therapeutics aimed at delaying age-related diseases. Its lead program uses a proprietary mRNA platform to boost endogenous secretion of soluble Klotho—a pleiotropic protein with potential benefits across multiple organ systems, including the brain, heart, kidneys, lungs, and bones. By restoring Klotho levels diminished by aging, disease, or genetics, Klothea aims to unlock a new therapeutic pathway for enhancing health span. The company is targeting Phase 1 clinical trials in early 2026, with metabolic syndrome as the first planned indication. Klothea is proud to partner with Healthy Longevity clinic that has been chosen as a semifinalist in the $101 million XPRIZE Healthspan competition for its approach to increase health span with our proprietary klotho mRNA therapy.